Glenmark Pharmaceuticals Limited has officially filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, prepared by Rauthan & Associates Company Secretaries LLP, confirms the company’s adherence to various SEBI regulations and guidelines throughout the review period. The document details compliance with listing obligations, disclosure requirements, and other statutory mandates, indicating a strong governance framework for the fiscal year 2025-26.
Glenmark Pharmaceuticals Files Annual Secretarial Compliance Report
Glenmark Pharmaceuticals Limited has formally submitted its Annual Secretarial Compliance Report for the financial year that concluded on March 31, 2026. This filing is in accordance with Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Report Prepared by Rauthan & Associates
The comprehensive report was meticulously prepared by Rauthan & Associates Company Secretaries LLP. Their examination covered all relevant documents, records, and explanations provided by Glenmark Pharmaceuticals Limited, as well as the company’s filings with stock exchanges and its official website. The review period specifically focused on the financial year 2025-26.
Scope of Compliance Examination
The examination by Rauthan & Associates encompassed compliance with the SEBI Act, 1992, and its associated regulations, circulars, and guidelines. This also included adherence to the Securities Contracts (Regulation) Act, 1956 (SCRA), and rules made thereunder. Specifically, the report assesses compliance with:
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR’);
- SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018;
- SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- SEBI (Buyback of Securities) Regulations, 2018 (not applicable to Glenmark during the review period);
- SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021;
- SEBI (Issue and Listing of Non-Convertible Securities) Regulations, 2021 (not applicable);
- SEBI (Prohibition of Insider Trading) Regulations, 2015, including the maintenance of a Structured Digital Database (SDD);
- SEBI (Depositories and Participant) Regulations, 2018;
- SEBI (Delisting of Equity Shares) Regulations, 2021 (not applicable).
Key Compliance Areas Assessed
The report confirms that Glenmark Pharmaceuticals Limited has generally complied with the applicable regulations and guidelines. Key areas reviewed and confirmed as compliant include:
- Secretarial Standards: Compliance with applicable Secretarial Standards issued by the Institute of Company Secretaries of India (ICSI).
- Policies: Adoption and timely updation of all applicable policies under SEBI Regulations, with board approval.
- Website Maintenance: Ensuring a functional website with timely dissemination of information and accurate web-links for corporate governance reports.
- Director Disqualification: Confirmation that no director is disqualified under Section 164 of the Companies Act, 2013.
- Subsidiary Management: Proper identification of material subsidiaries and adherence to disclosure requirements.
- Document Preservation: Compliance with SEBI regulations for preserving and maintaining records.
- Performance Evaluation: Conducting performance evaluations for the Board, Independent Directors, and Committees.
- Related Party Transactions: Obtaining prior approval from the Audit Committee for related party transactions.
- Disclosure of Events: Providing all required disclosures under Regulation 30 of SEBI LODR Regulations within prescribed timelines.
- Insider Trading: Compliance with Regulation 3(5) and 3(6) of SEBI (Prohibition of Insider Trading) Regulations, 2015.
The report also notes that there were no actions taken by SEBI or Stock Exchanges against the listed entity or its related parties during the review period, and there were no instances of statutory auditor resignations from the company or its material subsidiaries.
Assumptions and Limitations
Rauthan & Associates highlighted that the responsibility for ensuring the authenticity of furnished information lies with the management of Glenmark Pharmaceuticals Limited. Their report is based on an examination of relevant documents and information provided, and it does not constitute an audit or an expression of opinion on the company’s financial records or future viability. The report is strictly for the purpose of fulfilling the compliance requirements of Regulation 24A of the SEBI LODR Regulations, 2015.
The company secretary, Harish Kuber, signed off on the submission to the stock exchanges, acknowledging the attached report.
Source: BSE
